Dapagliflozin Phase 3 study also showed that Dapagliflozin plus glimepiride achieved reductions in the secondary efficacy endpoints of change in total body weight, oral glucose tolerance test (OGTT) and fasting plasma glucose (FPG) levels from baseline at week 24 compared to placebo plus glimepiride.
Additionally, more people taking Dapagliflozin and glimepiride were able to achieve a target HbA1c of less than 7% compared to patients taking glimepiride alone.
Dapagliflozin, an investigational compound, is a sodium-glucose cotransporter-2 (SGLT2) inhibitor and is currently in Phase 3 trials as a once-daily oral therapy for the treatment of adult patients with type 2 diabetes.
SGLT2 inhibitors, which act independently of insulin mechanisms, facilitate the excretion of glucose and associated calories in the urine, thereby lowering blood glucose levels.
Silesian Medical University Department of Internal Diseases Diabetology & Nephrology professor and principal investigator of the study Krzysztof Strojek said that the study, which adds to the Phase 3 data available for the investigational compound, demonstrated that Dapagliflozin improved glycemic control, as measured by HbA1c, FPG and PPG, in adult patients with type 2 diabetes when added to the commonly used oral diabetic agent, glimepiride.